Belite Bio, Inc
BLTE
$148.60
-$3.19-2.10%
NASDAQ
| 09/30/2025 | 12/31/2024 | 09/30/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 673.71% | 100.81% | 30.66% | 30.66% | 383.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 283.29% | 64.73% | -11.14% | -11.14% | 156.09% |
| Operating Income | -283.29% | -64.73% | 11.14% | 11.14% | -156.09% |
| Income Before Tax | -302.44% | -44.47% | 20.62% | 20.62% | -139.68% |
| Income Tax Expenses | -- | 100.00% | -- | -100.00% | -- |
| Earnings from Continuing Operations | -302.37% | -44.49% | 20.63% | 20.63% | -139.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -302.37% | -44.49% | 20.63% | 20.63% | -139.58% |
| EBIT | -283.29% | -64.73% | 11.14% | 11.14% | -156.09% |
| EBITDA | -284.41% | -64.95% | 11.33% | 11.38% | -156.18% |
| EPS Basic | -271.68% | -30.01% | 29.35% | 29.35% | -89.55% |
| Normalized Basic EPS | -271.66% | -30.07% | -- | -- | -- |
| EPS Diluted | -271.68% | -30.01% | 29.35% | 29.35% | -89.55% |
| Normalized Diluted EPS | -271.66% | -30.07% | -- | -- | -- |
| Average Basic Shares Outstanding | 8.26% | 11.10% | 12.34% | 12.34% | 26.37% |
| Average Diluted Shares Outstanding | 8.26% | 11.10% | 12.34% | 12.34% | 26.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |